SAB Biotherapeutics (SABS) grants 240,000 options to new director

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. granted director Rita Jain a new equity award. On January 5, 2026, she received a stock option to purchase 240,000 shares of common stock at an exercise price of $3.74 per share. This represents her inaugural grant as a member of the company’s Board of Directors.

The option expires on January 5, 2036 and the underlying shares vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029. The award was made under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by Jain.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)(2)	$3.74	01/05/2026		A		240,000		(1)	01/05/2036	Common Stock	240,000	$0	240,000	D

Explanation of Responses:

1. Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.

2. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

	/s/ Grant Levine, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SAB Biotherapeutics (SABS) report for Rita Jain?

The company reported that director Rita Jain received a stock option grant for 240,000 shares of SAB Biotherapeutics common stock on January 5, 2026.

What is the exercise price and term of Rita Jain’s SAB Biotherapeutics stock options?

The stock option granted to Rita Jain has an exercise price of $3.74 per share and an expiration date of January 5, 2036.

How do Rita Jain’s SAB Biotherapeutics stock options vest?

The 240,000-share option vests in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029.

Why was this option grant made to SAB Biotherapeutics director Rita Jain?

The filing states that the grant represents the inaugural option award to Rita Jain as a member of the Board of Directors of SAB Biotherapeutics.

Under which equity plan were Rita Jain’s SAB Biotherapeutics options granted?

The option award to Rita Jain was made pursuant to SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended.

Does Rita Jain hold the SAB Biotherapeutics stock options directly or indirectly?

The Form 4 indicates that the 240,000 stock options are held directly (D) by Rita Jain.